Skip to main content
SpringerLink
Log in

Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The objective of this study was to compare concomitant chemoradiotherapy based on weekly low-dose gemcitabine versus weekly low-dose paclitaxel in locally advanced head and neck squamous cell carcinoma. Previously, untreated patients with locally advanced squamous cell carcinoma of the head and neck were randomly assigned to one of the two concomitant chemoradiation regimens: (1) weekly gemcitabine at a dose of 100 mg/m2 over 30 min 1–2 h before radiotherapy and (2) weekly paclitaxal at a dose of 20 mg/m2 over 60 min 4–6 h before radiotherapy. The planned radiotherapy dose was 65 Gy over 6.5 weeks in 32 settings. Two hundred and sixteen patients were randomly divided into 2 groups: group A (110 patients) and group B (106 patients) who received concomitant weekly low-dose gemcitabine and low-dose paclitaxal, respectively, with the radiotherapy protocol. The hematological toxicity was generally mild. On the contrary, non-hematologic toxicities were severe. Grade III mucositis occurred in 36% in group A and in 24% in group B (P = 0.04). Moreover, grade III dermatitis were encountered in 24% in group A and 13% in group B (P = 0.049). Thirty-two (29%) of group A and 18(17%) of group B patients required enteral or parenteral feeding (P = 0.01). Sixteen (15%) of group A and 6 (6%) of group B required enteral or parenteral feeding that lasted for 6 months (P = 0.03). Regarding the late effect on swallowing, 8% of patients in group A and 2% of patients in group B required enteral or parenteral feeding for more than 6 months (P = 0.035). Response rates were 78 and 89% in groups A and B, respectively (P = 0.038). The 2-year progression-free survival figures were 54 and 64% of groups A and B, respectively; however, the 2-year overall survival figures were 56 and 67%, respectively. On the other hand, the 3-year progression-free survival figures were 39 and 48% for groups A and B, respectively, while the 3-year overall survival figures were 45 and 49%, respectively (P = 0.05). Both concomitant chemoradiotherapy regimens were easily given in the outpatient clinic. The regimen based on paclitaxel was significantly more tolerable and effective; however, the difference was not enormous.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709.

    Article  PubMed  CAS  Google Scholar 

  2. Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, et al. Combined radiotherapy and chemotherapy with belomycin and methotrexate for advanced inoperable head and neck cancer. J Clin Oncol. 1987;5:1410–8.

    PubMed  CAS  Google Scholar 

  3. Gupta NK, Pointon RC, Wilkinson PM. A randomized clinical trial to compare radiotherapy with radiotherapy and methotexate given synchronously in head and neck cancer. Clin Radiol. 1987;38:575–81.

    Article  PubMed  CAS  Google Scholar 

  4. Merlano M, Vitale V, Rossa R, Benasso M, Corvo R, Forastiere A, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Eng J Med. 1992;237:1115–21.

    Article  Google Scholar 

  5. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Eng J Med. 1998;338:1798–804.

    Article  CAS  Google Scholar 

  6. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–6.

    Article  PubMed  CAS  Google Scholar 

  7. Hafty BG, Son YH, Papec R, Sasaki CT, Weissberg JB, Fischer D, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol. 1997;15:268–76.

    Google Scholar 

  8. Wendt TG, Grabenbauer GC, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter trial. J Clin Oncol. 1998;16:1318–24.

    PubMed  CAS  Google Scholar 

  9. Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2′, 2′-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991;309A:125–30.

    PubMed  CAS  Google Scholar 

  10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanism of action, and self potentiation. Semin Oncol. 1995;22(Supp 11):3–10.

    PubMed  CAS  Google Scholar 

  11. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-cancer Drugs. 1995;6(suppl 6):7–13.

    Article  PubMed  CAS  Google Scholar 

  12. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by by 2″, 2″-difluoro-2″-deoxycytidine. Int J Radiat Oncol Biol Phy. 1996;34:867–72.

    Article  CAS  Google Scholar 

  13. Hernandez P, Oivera P, Duenas-Gonzalez A, Pérez-Pastenes MA, Zárate A, Maldonado V, et al. Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol. 2001;48:488–92.

    Article  PubMed  CAS  Google Scholar 

  14. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2″, 2″-difluoro-2″-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994;54:3218–23.

    PubMed  CAS  Google Scholar 

  15. Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB. Preclinical In Vivo activity of 2″, 2″-difluorodeoxy cytidine against head and neck cancer. Cancer Res. 1991;51:211–4.

    PubMed  CAS  Google Scholar 

  16. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, et al. Enhancement of radiation induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest. 1997;5:62–71.

    Article  CAS  Google Scholar 

  17. Eisbruch A, Shewach DS, Urba S, Bradford CR, Littles JF, Teknos TN et al. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: high mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol. 1997;16:386a (Abstr 1377).

    Google Scholar 

  18. Aguilar-Ponce J, Granados-García M, Villavicencio V, Poitevin-Chacón A, Green D, Dueñas-González A, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2004;15:301–7.

    Article  PubMed  CAS  Google Scholar 

  19. Schiff PB, Fant J, Howrwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–7.

    Article  PubMed  CAS  Google Scholar 

  20. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 1980;77:1561–5.

    Article  PubMed  CAS  Google Scholar 

  21. Terasima R, Tolmach LJ. X-ray sensitivity and DNA synthesis in synchronous populations of Hela cells. Science. 1963;140:490–2.

    Article  PubMed  CAS  Google Scholar 

  22. Milas L, Milas MM, Moson KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9:12–26.

    PubMed  CAS  Google Scholar 

  23. Elomaa L, Joensuu H, Kulmala J, Klemi P, Grénman R. Squamous cell carcinoma is highly sensitive to taxol, a possible new radiation sensitizer. Acta Otolaryngol (Stockh). 1995;115:340–4.

    Article  CAS  Google Scholar 

  24. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 1996;65:5198–204.

    Google Scholar 

  25. Rosenthal DI, Carbone DP. Taxol plus radiation for head and neck cancer. J Infus Chemoth. 1995;5:46–54.

    CAS  Google Scholar 

  26. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995;55:3564–8.

    PubMed  CAS  Google Scholar 

  27. Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF, et al. Radiotherapy and concomitantly weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer: results from a phase I trial. Int J Radiat Oncol Biol Phys. 1997;38:691–6.

    Article  PubMed  CAS  Google Scholar 

  28. Seif Eldein I, Ismail K, Hablas A, Hussein H, Elhamzawy H, Ramadan M editors. Cancer Egypt Gharbia, triennial report of 2000–2002, Gharbia Population-Based Cancer Registery. 1st ed. Tanta: El Meahy press; 2007. pp. 96–03.

  29. Choeng N, Vores E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008;58:32–53.

    Article  Google Scholar 

  30. Adelstein D, Rodriguez C. Current and emerging standards of concomitant chemoradiotherapy. Semin Oncol. 2008;35:211–20.

    Article  PubMed  Google Scholar 

  31. Bourhis J, Le Maître A, Baujat B, Audry H, Pignon JP. Individual patients’ data meta-analysis in head and neck cancer. Curr Opin Oncol. 2007;19:188–94.

    Article  PubMed  Google Scholar 

  32. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol. 2001;19:792–9.

    PubMed  CAS  Google Scholar 

  33. Hainsworth JD, Meluch AA, McClurkan S, Gray JR, Stroup SL, Burris HA 3rd, et al. Induction paclitaxel, carboplatin, and infusional 5-Fu followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J. 2002;8:311–21.

    Article  PubMed  Google Scholar 

  34. Jain RK, Kirar P, Gupta G, Dubey S, Gupta SK, Goyal J. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers. In J Cancer. 2009;46:50–3.

    CAS  Google Scholar 

  35. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systemic literature review. Radiother Oncol. 2003;66:253–62.

    Article  PubMed  Google Scholar 

  36. Hoffstetter S, Marchal C, Peiffert D, Luporsi E, Lapeyre M, Pernot M, et al. Treatment duration as a prognostic factor for local control and survival in epidermoid carcinoma of the tonsillar region treated by combined external beam irradiation and brachytherapty. Radiother Oncol. 1997;45:141–8.

    Article  PubMed  CAS  Google Scholar 

  37. Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwiński R, Maciejewski B, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54:229–36.

    PubMed  Google Scholar 

  38. Suwinski R, Sowa A, Rutkowski T, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys. 2003;56:399–412.

    Article  PubMed  Google Scholar 

  39. Langendijk JA, de Jong MA, Leemans CR, de Bree R, Smeele LE, Doornaert P, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57:693–700.

    Article  PubMed  CAS  Google Scholar 

  40. Lövey J, Koronczay K, Remenár E, Csuka O, Németh G. Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol. 2003;68:171–4.

    Article  PubMed  Google Scholar 

  41. Specenier PM, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing MT, et al. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long term follow up data. Ann Oncol. 2007;18:1856–60.

    Article  PubMed  CAS  Google Scholar 

  42. Chauhan A, Singh H, Sharma T, Manocha KK. Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas. Afr Health Sci. 2008;8:149–55.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology and Nuclear Medicine, University of Mansoura, Mansoura, Egypt

    Amal Ahmed-Fouad Halim, Hanan Ahmed Wahba & Hend Ahmed El-Hadaad

  2. Community Medicine, Faculty of Medicine, University of Mansoura, Mansoura, Egypt

    Ahmed Abo-Elyazeed

Authors
  1. Amal Ahmed-Fouad Halim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanan Ahmed Wahba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hend Ahmed El-Hadaad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Abo-Elyazeed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hend Ahmed El-Hadaad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halim, A.AF., Wahba, H.A., El-Hadaad, H.A. et al. Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study. Med Oncol 29, 279–284 (2012). https://doi.org/10.1007/s12032-010-9811-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9811-x

Keywords

Search

Navigation